Quick Answer
KALA BIO, Inc. reported Stockholders Equity of $12.33 million for the year ending 2024.
- KALA BIO, Inc. showed an increase of +64.3% in Stockholders Equity from 2023 to 2024.
- This data is from KALA BIO, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2014 to 2024 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: -$107.42 million | Q3 2017: $98.86 million | Q1 2018: $80.27 million | Q2 2018: $68.09 million | Q3 2018: $54.93 million | Q1 2019: $82.37 million | Q2 2019: $61.07 million | Q3 2019: $43.06 million | Q1 2020: $141.51 million | Q2 2020: $128.94 million | Q3 2020: $106.03 million | Q1 2021: $109.79 million | Q2 2021: $84.27 million | Q3 2021: $61.47 million | Q1 2022: -$5.28 million | Q2 2022: -$31.55 million | Q3 2022: -$968.0 thousand | Q1 2023: $23.46 million | Q2 2023: $17.49 million | Q3 2023: $11.22 million | Q4 2023: $7.50 million | Q1 2024: $6.66 million | Q2 2024: $13.72 million | Q3 2024: $6.86 million | Q4 2024: $12.33 million | Q1 2025: $5.71 million | Q2 2025: -$3.21 million | Q3 2025: -$8.67 million.
- Over the full 11 years of available data (2014 to 2024), KALA BIO, Inc.'s Stockholders Equity has grown by 130.3%.
- Historical annual values: Fiscal year 2024: $12.33 million | Fiscal year 2023: $7.50 million | Fiscal year 2022: $18.97 million | Fiscal year 2021: $16.80 million | Fiscal year 2020: $100.00 million | Fiscal year 2019: $29.69 million | Fiscal year 2018: $104.98 million | Fiscal year 2017: $89.68 million | Fiscal year 2016: -$87.76 million | Fiscal year 2015: -$56.66 million | Fiscal year 2014: -$40.72 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: